Literature DB >> 8154875

Cloning of human anti-GM1 antibodies from motor neuropathy patients.

H J Willison1, G Paterson, P G Kennedy, J Veitch.   

Abstract

Patients with multifocal motor neuropathy frequently have elevated titers of serum antibodies reactive with GM1 ganglioside. Although these antibodies may cause the syndrome, this has yet to be proven directly. As part of our studies on the nature and pathogenic potential of anti-GM1 antibodies, we have cloned B cells from the peripheral blood of 3 patients with multifocal motor neuropathy and generated four stable heterohybridoma cell lines secreting human monoclonal IgM anti-GM1 antibodies. In this report we describe the basic properties of these monoclonal antibodies in comparison with the patient's sera from which they were derived. The antibodies all differ in their pattern of reactivity with GM1 and other Gal(beta 1-3)GalNAc-containing glycoconjugates. They have widely varying thermal ranges and their reactivities are strongly influenced by the presence of accessory lipids. Affinity purification of the patient's sera with GM1 led to the identification of previously unrecognized paraproteins that were resolvable above the background of polyclonal anti-GM1 IgM. Our data demonstrate considerable heterogeneity in the immune response to GM1 both within individual sera and between different patients, which is likely to be of importance to their role in disease pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8154875     DOI: 10.1002/ana.410350416

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  12 in total

Review 1.  Specificity of antiglycolipid antibodies.

Authors:  N Baumann
Journal:  Clin Rev Allergy Immunol       Date:  2000-08       Impact factor: 8.667

2.  Antibodies to heteromeric glycolipid complexes in multifocal motor neuropathy.

Authors:  F Galban-Horcajo; A M Fitzpatrick; A J Hutton; S M Dunn; G Kalna; K M Brennan; S Rinaldi; R K Yu; C S Goodyear; H J Willison
Journal:  Eur J Neurol       Date:  2012-06-22       Impact factor: 6.089

Review 3.  Multifocal motor neuropathy.

Authors:  E Nobile-Orazio
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-06       Impact factor: 10.154

4.  Anti-GM1 antibodies in polyneuropathies of unknown origin.

Authors:  J Finsterer; W Muellbacher; W M Halbmayer; M Fischer; B Mamoli
Journal:  J Clin Pathol       Date:  1996-05       Impact factor: 3.411

Review 5.  Autoimmune responses in peripheral nerve.

Authors:  H P Hartung; H Willison; S Jung; M Pette; K V Toyka; G Giegerich
Journal:  Springer Semin Immunopathol       Date:  1996

Review 6.  Immunological findings in amyotrophic lateral sclerosis.

Authors:  J P Antel; N R Cashman
Journal:  Springer Semin Immunopathol       Date:  1995

Review 7.  Antiglycolipid antibodies in peripheral neuropathy: fact or fiction?

Authors:  H J Willison
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

8.  A somatically mutated human antiganglioside IgM antibody that induces experimental neuropathy in mice is encoded by the variable region heavy chain gene, V1-18.

Authors:  H J Willison; G M O'Hanlon; G Paterson; J Veitch; G Wilson; M Roberts; T Tang; A Vincent
Journal:  J Clin Invest       Date:  1996-03-01       Impact factor: 14.808

9.  Human monoclonal immunoglobulin M antibodies to ganglioside GM1 show diverse cross-reactivities with lipopolysaccharides of Campylobacter jejuni strains associated with Guillain-Barré syndrome.

Authors:  M M Prendergast; H J Willison; A P Moran
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

10.  Structure of Campylobacter jejuni lipopolysaccharides determines antiganglioside specificity and clinical features of Guillain-Barré and Miller Fisher patients.

Authors:  C W Ang; J D Laman; H J Willison; E R Wagner; H P Endtz; M A De Klerk; A P Tio-Gillen; N Van den Braak; B C Jacobs; P A Van Doorn
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.